Investment Summary

Enavate Sciences Invests In Compass Therapeutics

On November 2, 2022, Enavate Sciences invested in life science company Compass Therapeutics

Investment Highlights
  • This is Enavate Sciences’ 1st transaction in the Life Science sector.
  • This is Enavate Sciences’ 1st transaction in the United Kingdom.

Investment Summary

Date 2022-11-02
Target Compass Therapeutics
Sector Life Science
Investor(s) Enavate Sciences
Deal Type Stake Purchase

Target

Compass Therapeutics

Boston, United Kingdom
Compass Therapeutics is a clinical-stage biopharmaceutical company developing proprietary antibody therapeutics to treat both solid tumors and hematologic malignancies. Compass is leveraging its proprietary StitchMabs™ and common light-chain-based multispecific platforms to empirically identify multispecific and combinations of antibody therapeutics that synergistically modulate key nodes in the immune system. Compass Therapeutics was incorporated in 2014 and is based in Boston, Massachusetts.

Search 214,356 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Investor(S) 1

Investor

Enavate Sciences

New York, New York, United States

Category Company
Sector Financial Services
DESCRIPTION

Enavate Sciences is a platform dedicated to supporting therapeutic companies advancing medicines and enabling technologies with transformative potential to address patient need. Through the application of capital support and operational experience, Enavate strives to enable and empower a diverse portfolio of therapeutics companies to accelerate innovation. Enavate Sciences is based in New York, New York.


DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Stake Purchase M&A Deals 1 of 1
Country: United Kingdom M&A 1 of 1
Year: 2022 M&A 1 of 1